Optimistic Buy Rating for Kronos Bio Amid Positive KB-0742 Trial Progress and Expanding Oncology Pipeline
Kronos Bio Analyst Ratings
Buy Rating Affirmed for Kronos Bio Amid Promising KB-0742 Data and Solid Financial Footing
Analysts Offer Insights on Healthcare Companies: Kronos Bio (KRON), Jazz Pharmaceuticals (JAZZ) and KalVista Pharmaceuticals (KALV)
Analysts Offer Insights on Healthcare Companies: Kronos Bio (KRON), Axsome Therapeutics (AXSM) and Sotera Health (SHC)
Piper Sandler Remains a Buy on Kronos Bio (KRON)
Buy Rating Affirmed for Kronos Bio Amid Restructuring and Promising KB-0742 Clinical Data
Piper Sandler Trims Price Target on Kronos Bio to $6 From $7, Keeps Overweight Rating
Piper Sandler Keeps Their Buy Rating on Kronos Bio (KRON)
Kronos Bio Receives Buy Rating From Analyst Amid Promising Pipeline Developments
HC Wainwright & Co. Maintains Buy on Kronos Bio, Lowers Price Target to $2.5
Kronos Bio Analyst Ratings
TD Cowen Sticks to Its Buy Rating for Kronos Bio (KRON)
Kronos Bio Analyst Ratings
Strategic Financial Management and Promising Clinical Trials Underpin Buy Rating for Kronos Bio
Kronos Bio (KRON) Gets a Buy From TD Cowen
Analysts' Opinions Are Mixed on These Healthcare Stocks: Kronos Bio (KRON), Quest Diagnostics (DGX) and UnitedHealth (UNH)
HC Wainwright & Co. Maintains Buy on Kronos Bio, Lowers Price Target to $9
Kronos Bio Analyst Ratings
Berenberg Bank Sticks to Their Buy Rating for Kronos Bio (KRON)